Opendata, web and dolomites

Pituitary enhancers SIGNED

Identification and functional validation of novel enhancer sequences involved in pituitary gland development and pathology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Pituitary enhancers project word cloud

Explore the words cloud of the Pituitary enhancers project. It provides you a very rough idea of what is the project "Pituitary enhancers" about.

silico    performed    verified    human    expression    linked    physiological    gpr101    remarkably    luciferase    accessibility    perform    marks    putative    causing    local    variations    regulation    health    genome    transcription    transcriptional    lag    sanger    regulates    assays    interactions    structural    pathological    children    region    preliminary    pathologies    domain    central    overexpression    gene    histone    tumors    tumoral    vitro    underlying    structure    patients    disrupt    enhancers    profile    showing    there    clinical    enhancer    promoter    duplicated    tested    regulatory    creation    novo    cells    conducting    disorders    4c    hypothesis    chip    gap    located    mutations    characterization    fundamental    duplications    indicator    acrogigantism    screen    seq    normal    methylation    pituitary    pursuing    place    gpr10    de    cnv    mechanisms    molecular    elucidate    sequencing    reporter    functional    chromatin    functionally    sequences    abnormal    validate   

Project "Pituitary enhancers" data sheet

The following table provides information about the project.

Coordinator
HUMANITAS MIRASOLE SPA 

Organization address
address: VIA MANZONI 56
city: ROZZANO (MI)
postcode: 20100
website: www.humanitas.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 183˙473 €
 EC max contribution 183˙473 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2020
 Duration (year-month-day) from 2020-03-16   to  2022-03-15

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HUMANITAS MIRASOLE SPA IT (ROZZANO (MI)) coordinator 183˙473.00

Map

 Project objective

There is a fundamental gap in understanding how the GPR101 gene regulates human growth in physiological and pathological conditions. Children’s growth is remarkably clinical relevant and is an important indicator of their health and general well-being. The specific objective of this proposal is to identify the molecular mechanisms underlying GPR101 overexpression in the pituitary tumors of children with GPR101 duplications causing X-linked acrogigantism (X-LAG). My central hypothesis is that GPR101 duplications disrupt the structure of the local chromatin, leading to the creation of a new chromatin domain where de novo enhancer-promoter interactions take place, causing abnormal GPR101 expression. This hypothesis will be tested by pursuing three specific aims: 1. Elucidate the transcriptional regulation of GPR101 in normal and pathological conditions 2. Identify and functionally characterize novel pituitary-specific enhancer sequences 3. Investigate these regulatory sequences in patients with different pituitary pathologies. To achieve aim 1) I will perform an in vitro functional characterization of GPR101 promoter: promoter activity will be studied by luciferase-based reporter assays, by conducting a methylation analysis, and by determining its accessibility to transcription factors. To achieve aim 2) I will validate my preliminary results showing the formation of a novel chromatin domain by 4C-Seq. Four putative enhancer sequences located within the duplicated GPR10 region and identified in silico will be functionally evaluated in vitro to establish their impact on transcriptional activity. To identify novel pituitary-specific enhancers, a whole-genome profile of enhancer-specific histone marks will be performed in normal and tumoral pituitary cells by ChIP-Seq. To achieve aim 3) I will screen patients with different pituitary disorders for mutations (Sanger sequencing) and structural variations (CNV assays) in the functionally-verified enhancers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PITUITARY ENHANCERS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PITUITARY ENHANCERS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Widow Spider Mating (2020)

Immature mating as a novel tactic of an invasive widow spider

Read More  

TARGET SLEEP (2020)

Boosting motor learning through sleep and targeted memory reactivation in ageing and Parkinson’s disease

Read More  

DECEYEDE (2020)

The effects of aging in the control of eye movements and its relation to perceptual and motor decisions

Read More